source
- FDA criticizes Lundbeck for webpages on migraine treatment VyeptiThe FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages that made allegedly inflated claims regarding the efficacy of its migraine drug. In an untitled letter sent la…Endpoints · 21d ago↗ source
- GSK ends brain drug alliance with AlectorClinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.BioPharma Dive · 21d ago↗ source
- FDA quietly stops releasing CRLsThe FDA has paused its public release of pharma rejection letters as the agency seeks to avoid litigation around releasing the often sensitive information. The pause follows a law firm in AprilEndpoints · 21d ago